Products for Research Use Only

Icotrokinra

CAT: 0804-HY-P10587-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P10587-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease[1].
CAS Number
2763602-16-8
Product Name Alternative
JNJ-77242113; JNJ-2113; PN-235
UNSPSC
12352209
Target
IFNAR; Interleukin Related; STAT
Type
Peptides
Related Pathways
Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/icotrokinra.html
Purity
99.9
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL
Smiles
NCCOC(C=C1)=CC=C1C[C@H](NC([C@H]2NC([C@@H](NC([C@@H](NC([C@](NC([C@@H](NC([C@H](C(C)(SSC2(C)C)C)NC(C)=O)=O)CC(N)=O)=O)([H])[C@H](O)C)=O)CC(C3=CC=C4)=CNC3=C4C)=O)CCCCNC(C)=O)=O)=O)C(N[C@@H](CC5=CC6=C(C=CC=C6)C=C5)C(NC7(CCOCC7)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](C(N(C)CC(N)=O)=O)CC8=CN=CC=C8)=O)=O)=O)=O)=O
Molecular Formula
C90H120N20O22S2
Molecular Weight
1898.17
References & Citations
[1]Fourie AM, et al., JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans. Sci Rep. 2024 Jul 30;14 (1) :17515.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
Phase 3
Isoform
IL-23